The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review

The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review

Juan Yang,1 Kyung-Min Shin,2 Alex Do,1 Dennis M Bierle,1 Abd Moain Abu Dabrh,3 Ziying Yin,4 Brent A Bauer,1 Arya B Mohabbat1 1Division of General Internal Medicine, Mayo Clinic, Rochester, MN, 55905, USA; 2KM Science Research Division, Korea Institute of Oriental Medicine, Daejeon, 34054, South Kore...

Full description

Bibliographic Details
Main Authors:	Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB
Format:	Article
Language:	English
Published:	Dove Medical Press 2023-03-01
Series:	Journal of Pain Research
Subjects:	fibromyalgia naltrexone low-dose naltrexone chronic pain review
Online Access:	https://www.dovepress.com/the-safety-and-efficacy-of-low-dose-naltrexone-in-patients-with-fibrom-peer-reviewed-fulltext-article-JPR

Similar Items

A systematic literature review on the clinical efficacy of low dose naltrexone and its effect on putative pathophysiological mechanisms among patients diagnosed with fibromyalgia
by: Sarah Partridge, et al.
Published: (2023-05-01)

Efficacy of Low-Dose Naltrexone and Predictors of Treatment Success or Discontinuation in Fibromyalgia and Other Chronic Pain Conditions: A Fourteen-Year, Enterprise-Wide Retrospective Analysis
by: C. Noelle Driver, et al.
Published: (2023-04-01)

Association of low-dose naltrexone and transcranial direct current stimulation in fibromyalgia: a randomized, double-blinded, parallel clinical trial
by: Tânia Maria Hendges de Paula, et al.
Published: (2023-07-01)

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
by: Marianna Ciwun, et al.
Published: (2024-03-01)

Low-Dose Naltrexone (LDN) for Chronic Pain at a Single Institution: A Case Series
by: McKenzie-Brown AM, et al.
Published: (2023-06-01)

Opiate Antagonists for Chronic Pain: A Review on the Benefits of Low-Dose Naltrexone in Arthritis versus Non-Arthritic Diseases
by: Praneet Dara, et al.
Published: (2023-06-01)

Precipitated withdrawal with kratom use following naltrexone administration
by: Jarka Courtney PharmD, BCPS, BCPP, et al.
Published: (2023-06-01)

Effective Doses of Low-Dose Naltrexone for Chronic Pain – An Observational Study
by: Marcus NJ, et al.
Published: (2024-03-01)

The efficacy and safety of oral low dose naltrexone versus placebo in the patients with lichen planopilaris: a randomized controlled clinical trial
by: Vahideh Lajevardi, et al.
Published: (2022-02-01)

Dominant Dystrophic Epidermolysis Bullosa Pruriginosa Responding to Naltrexone Treatment
by: Kristine A.U. Pallesen, et al.
Published: (2019-09-01)

Low-dose naltrexone and NAD+ for the treatment of patients with persistent fatigue symptoms after COVID-19
by: Anar Isman, et al.
Published: (2024-03-01)

Thermosensitive Gels Used to Improve Microneedle-Assisted Transdermal Delivery of Naltrexone
by: Kevin V. Tobin, et al.
Published: (2021-03-01)

The effectiveness of naltrexone combined with current smoking cessation medication to attenuate post smoking cessation weight gain: a literature review
by: Raewyn Rees, et al.
Published: (2017-12-01)

Evaluation of Different Doses of Fentanyl in Controlling Agitation in Acute Opioid Withdrawal Syndrome Induced by Naltrexone Misuse
by: Farzad Gheshlaghi, et al.
Published: (2012-03-01)

Naltrexone-induced acute generalized exanthematous pustulosis
by: Jason Eakes, BS, et al.
Published: (2023-09-01)

Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells
by: Natalia Kučić, et al.
Published: (2021-08-01)

Naltrexone Implant for Opioid Use Disorder
by: Amber N. Edinoff, et al.
Published: (2021-12-01)

Exploring genetic predictors of naltrexone treatment response in opioid use disorder
by: Е. A. Blokhina ., et al.
Published: (2019-12-01)

Kratom-induced transaminitis with subsequent precipitated opioid withdrawal following naltrexone
by: Aimee N. Jensen, PharmD, BCPS, BCPP, et al.
Published: (2021-05-01)

Design and Characterization of Spray-Dried Chitosan-Naltrexone Microspheres for Microneedle-Assisted Transdermal Delivery
by: Abayomi T. Ogunjimi, et al.
Published: (2020-05-01)

Variability of response to pharmacotherapy of naltrexone and guanfacin in patients with opioid dependence syndrome: pharmacogenetic aspect
by: V. Ya Palatkin, et al.
Published: (2019-12-01)

Probing the Release of Bupropion and Naltrexone Hydrochloride Salts from Biopolymeric Matrices of Diverse Chemical Structures
by: Angeliki Siamidi, et al.
Published: (2021-04-01)

Naltrexone engages a brain reward network in the presence of reward-predictive distractor stimuli in males
by: Cory N. Spencer, et al.
Published: (2023-09-01)

Long-Term Effects of Low-Dose Naltrexone on Immunomodulatory Properties of Human Adipose-Derived Mesenchymal Stem Cells
by: Romina Kazemi, et al.
Published: (2023-06-01)

New Construction of Functionalized CuO/Al<sub>2</sub>O<sub>3</sub> Nanocomposite-Based Polymeric Sensor for Potentiometric Estimation of Naltrexone Hydrochloride in Commercial Formulations
by: Amal M. Al-Mohaimeed, et al.
Published: (2021-12-01)

Low-dose naltrexone as treatment for epidermolysis bullosa pruriginosa–associated refractory pruritus
by: Lauren C. LaMonica, MPH, et al.
Published: (2023-08-01)

Chronic Intermittent Sucrose Consumption Facilitates the Ability to Discriminate Opioid Receptor Blockade with Naltrexone in Rats
by: David C. Jewett, et al.
Published: (2022-02-01)

Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone
by: Ann Tarja Karlsson, et al.
Published: (2021-09-01)

Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
by: Cho AR, et al.
Published: (2020-09-01)

Feasibility, Acceptability, and Preliminary Outcomes of an Integrated Telemedicine Intervention Combining Naltrexone and Cognitive Behavioral Therapy for Alcohol Use Disorder
by: Suzette Glasner, et al.
Published: (2022-11-01)

Molecular Basis of Inhibitory Mechanism of Naltrexone and Its Metabolites through Structural and Energetic Analyses
by: Martiniano Bello
Published: (2022-08-01)

Dissolution Assay of Bupropion/Naltrexone Hydrochloride Salts of Bilayer Composition Tablets Following the Development and Validation of a Novel HPLC Method
by: Anna Apostolidi, et al.
Published: (2022-11-01)

Steroid effects on the in vitro LH secretion from pituitary cells of sexually immature carp (Cyprinus carpio L.) under the influence of naltrexone and morphine
by: M. Sokolowska-Mikolajczyk, et al.
Published: (2010-06-01)

Systematic Analysis of the Service Process and the Legislative and Regulatory Environment for a Pharmacist-Provided Naltrexone Injection Service in Wisconsin
by: James H. Ford, et al.
Published: (2019-06-01)

Multimodal Acute Pain Management in the Parturient with Opioid Use Disorder: A Review
by: Koltenyuk V, et al.
Published: (2024-02-01)

The Review of pharmacological treatment registered for obesity in Poland
by: Julia Wyrwał, et al.
Published: (2024-02-01)

Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study
by: Sabrina Snyder, et al.
Published: (2024-02-01)

A Case Report of a Dual Diagnosis Patient: Naltrexone for the Treatment of Severe Nitrous Oxide Use Disorder with Associated Neurological and Psychiatric Sequelae
by: Paige Juliet Staudenmaier, et al.
Published: (2023-02-01)

Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations
by: R. R. Cook, et al.
Published: (2023-02-01)

Estimation of efficiency of double emulsification method for the preparation of naltrexone microspheres based on poly(lactic-co-glycolic acid) copolymer
by: E. A. Petrova, et al.
Published: (2013-04-01)